New daily pill for obesity and diabetes passes early safety check
NCT ID NCT05184322
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This early-stage study tested an oral tablet called ecnoglutide in 87 healthy adults to see if it is safe and how the body processes it. The drug is designed to help manage type 2 diabetes and obesity by mimicking a natural hormone that controls blood sugar and appetite. Since participants were healthy and the goal was safety, not treatment, this is a first step toward future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.